Fatma Tuba, Akdeniz

Profile Picture
Name Variants
Tuba Akdeniz Fatma
Tuba, Fatma
TUBA Akdeniz Fatma
Tuba, A.
Tuba, Akdeniz
Akdeniz F.T.
A. Fatma Tuba
A. F. TUBA
A. F. Tuba
A.,Fatma Tuba
Fatma Tuba, Akdeniz
Tuba, F.
Akdeniz Fatma TUBA
Akdeniz , Fatma Tuba
A., Fatma Tuba
Akdeniz Fatma Tuba
Akdeniz F. Tuba
Job Title
Dr. Öğr. Üyesi
Email Address
fatma.akdeniz@okan.edu.tr
ORCID ID
0000-0002-6076-0509
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

2

Articles

2

Citation Count

0

Supervised Theses

0

Filters

20242
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Citation Count: 0
    Investigation of Mirna-223-3p Expression in Non-small Cell Lung Cancers
    (int inst Anticancer Research, 2024) Barut, Zerrin; Akdeniz, Fatma Tuba; Isbir, Turgay; Genetik ve Biyomühendislik / Genetic and Bio-Engineering
    Background/ Aim: Lung cancer remains a principal cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC), representing a significant 80-85% of lung cancer diagnoses, often presents at an advanced stage, with many patients demonstrating local growth or metastasis at the time of detection. Consequently, there exists a pressing need for augmented research into the molecular and genetic underpinnings of this malignancy to facilitate the development of innovative therapeutic and preventative strategies. MicroRNA's (miRNAs) are non-coding RNA molecules, consisting of 20-25 nucleotides. Their involvement in epigenetic processes holds a pivotal role in the elucidation of molecular mechanisms. This study examined the potential of miRNA-223-3p as a biomarker in the diagnosis of patients with NSCLC. Materials and Methods: The expression analysis of miRNA-223-3p was performed in serum samples obtained from 18 patients diagnosed with NSCLC and a control group comprising 15 healthy volunteers. Results: The miRNA-223-3p Delta CT values in the serum samples taken from the patient group exhibited statistically significant elevation compared to those of the control group (p=0.043). Conclusion: The present study corroborates previous literature indicating elevated levels of miRNA-223-3p in NSCLC cases and thereby suggesting its potential role as a biomarker in NSCLC cases.
  • Thumbnail Image
    Article
    Citation Count: 0
    Unraveling the Impact of miRNA-17 in Glial Tumors and Cerebral Metastases: A Step Towards Enhanced Diagnosis and Prognosis
    (int inst Anticancer Research, 2024) Turk, Okan; Demirel, Nail; Yaltirik, Cumhur Kaan; Kaya, Mustafa; Sahin, Omer Faruk; Yilmaz, Seda Guelec; Isbir, Turgay; Genetik ve Biyomühendislik / Genetic and Bio-Engineering
    Background/Aim: MicroRNAs (miRNAs) have been identified as key regulators in various cancer types, including brain tumors. This study aimed to investigate the differential expression of miRNA-17 in glial tumors, cerebral metastases, and normal glial tissues. Materials and Methods: A total of 42 patients were included in this cross-sectional study. Tissue samples were obtained from patients with glial tumors or cerebral metastases and from normal glial tissues. miRNA-17 expression levels were computed by using real-time polymerase chain reaction. Receiver operating characteristics analysis was used to determine the predictive potential of miRNA-17. Results: In this study, we demonstrated a statistically significant difference in miRNA-17 expression levels between glial tumors and the control group (p=0.001), with higher miRNA-17 expression observed in glial tumors. Similarly, there was statistically higher miRNA-17 expression in metastatic cases compared with the control group (p=0.007). Conclusion: These findings suggest miRNA-17 might be a potential biomarker for differentiating glial tumors and cerebral metastases from normal glial tissue, although further research is necessary to validate these findings and investigate the potential role of miRNA-17 in the pathogenesis of these brain tumors.